Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(alefacept)
469 results
  • LiverTox: Clinical and Research Information on Drug-Induced Liver Injury: Alefacept [BOOK]
    LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda (MD)BOOK
  • Alefacept is a recombinant fusion protein of lymphocyte function associated antigen-3 (LFA-3) and immunoglobulin G dimer that acts to inactive T cells, and is an immunosuppressive agent that was previously used to treat moderate-to-severe plaque psoriasis. Alefacept is associated with a low rate of serum enzyme elevations during therapy and to rare instances of clinically apparent acute liver inj…
  • CD4+CD25+CD127hi cell frequency predicts disease progression in type 1 diabetes. [Journal Article]
    JCI Insight. 2021 01 25; 6(2)Narsale A, Lam B, … Davies JD
  • Transient partial remission, a period of low insulin requirement experienced by most patients soon after diagnosis, has been associated with mechanisms of immune regulation. A better understanding of such natural mechanisms of immune regulation might identify new targets for immunotherapies that reverse type 1 diabetes (T1D). In this study, using Cox model multivariate analysis, we validated our …
  • Comparing Beta Cell Preservation Across Clinical Trials in Recent-Onset Type 1 Diabetes. [Journal Article]
    Diabetes Technol Ther. 2020 12; 22(12):948-953.Jacobsen LM, Bundy BN, … Haller MJ
  • Several immunotherapies have demonstrated endogenous insulin preservation in recent-onset type 1 diabetes (T1D). We considered the primary results of rituximab, abatacept, teplizumab, alefacept, high-dose antithymocyte globulin (ATG), low-dose ATG, and low-dose ATG ± granulocyte-colony-stimulating factor trials in an attempt to rank the effectiveness of the agents studied. C-peptide 2-h area unde…
  • CD2 Immunobiology. [Review]
    Front Immunol. 2020; 11:1090.Binder C, Cvetkovski F, … Berglund D
  • The glycoprotein CD2 is a costimulatory receptor expressed mainly on T and NK cells that binds to LFA3, a cell surface protein expressed on e.g., antigen-presenting cells. CD2 has an important role in the formation and organization of the immunological synapse that is formed between T cells and antigen-presenting cells upon cell-cell conjugation and associated intracellular signaling. CD2 express…
  • Systemic treatments for alopecia areata: A systematic review. [Journal Article]
    Australas J Dermatol. 2019 Feb; 60(1):e1-e13.Lai VWY, Chen G, … Sinclair R
  • A range of systemic treatments are used for alopecia areata with variable evidence supporting efficacy. In this systematic review, we evaluated the evidence surrounding systemic treatments for alopecia areata, alopecia totalis and alopecia universalis. A systematic search was conducted of the peer-reviewed literature published between 1946 and March 2018 via Medline, Embase, Amed, the Cochrane Ce…
  • Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. [Review]
    Cochrane Database Syst Rev. 2017 12 22; 12:CD011535.Sbidian E, Chaimani A, … Le Cleach L
  • CONCLUSIONS: Our review shows that compared to placebo, the biologics ixekizumab, secukinumab, brodalumab, guselkumab, certolizumab, and ustekinumab are the best choices for achieving PASI 90 in people with moderate to severe psoriasis on the basis of moderate- to high-certainty evidence. At class level, the biologic treatments anti-IL17, anti-IL12/23, anti-IL23, and anti-TNF alpha were significantly more effective than the small molecules and the conventional systemic agents, too. This NMA evidence is limited to induction therapy (outcomes were measured between 12 to 16 weeks after randomisation) and is not sufficiently relevant for a chronic disease. Moreover, low numbers of studies were found for some of the interventions, and the young age (mean age of 44 years) and high level of disease severity (PASI 20 at baseline) may not be typical of patients seen in daily clinical practice.Another major concern is that short-term trials provide scanty and sometimes poorly reported safety data and thus do not provide useful evidence to create a reliable risk profile of treatments. Indeed, we found no significant difference in the assessed interventions and placebo in terms of SAEs. Methotrexate appeared to have the best safety profile, but as the evidence was of very low to moderate quality, we cannot be sure of the ranking. In order to provide long-term information on the safety of the treatments included in this review, it will be necessary to evaluate non-randomised studies and postmarketing reports released from regulatory agencies as well.In terms of future research, randomised trials comparing directly active agents are necessary once high-quality evidence of benefit against placebo is established, including head-to-head trials amongst and between conventional systemic and small molecules, and between biological agents (anti-IL17 versus anti-IL23, anti-IL23 versus anti-IL12/23, anti-TNF alpha versus anti-IL12/23). Future trials should also undertake systematic subgroup analyses (e.g. assessing biological-naïve patients, baseline psoriasis severity, presence of psoriatic arthritis, etc.). Finally, outcome measure harmonisation is needed in psoriasis trials, and researchers should look at the medium- and long-term benefit and safety of the interventions and the comparative safety of different agents.
  • Old and New Biological Therapies for Psoriasis. [Review]
    Int J Mol Sci. 2017 Nov 01; 18(11)Rønholt K, Iversen L
  • Biological therapy became available for psoriasis with the introduction of alefacept at the beginning of this century. Up to then, systemic treatment options comprised small molecule drugs, targeting the immune system in a non-specific manner. The first biologics targeted T-cell activation and migration and served as an alternative to small molecules. However, significant improvement in outcome w…
  • A novel therapeutic paradigm for patients with extensive alopecia areata. [Review]
    Expert Opin Biol Ther. 2016 08; 16(8):1005-14.Renert-Yuval Y, Guttman-Yassky E
  • Alopecia areata (AA) is a common, T-cell mediated, hair-centered skin disease that lacks efficacious, long-term therapies for extensive disease. Systemic immune suppressants are usually used, despite their nonspecific actions, often associated with substantial side effects. Although, the Th1 pathway was suggested as pivotal in the disease, recent studies suggest that Th2, Th9, phosphodiesterase (…
  • Can We Repurpose FDA-Approved Alefacept to Diminish the HIV Reservoir? [Journal Article]
    Immunotherapy (Los Angel). 2015 Dec; 1(1)Zaidi A, Meng Q, Popkin D
  • Current anti-retroviral treatment (ART) for HIV is effective in maintaining HIV at undetectable levels. However, cessation of ART results in immediate and brisk rebound of viremia to high levels. This rebound is driven by an HIV reservoir mainly enriched in memory CD4+ T cells. In order to provide any form of functional HIV Cure, elimination of this viral reservoir has become the focus of current…
  • Targeting memory T cells in type 1 diabetes. [Review]
    Curr Diab Rep. 2015 Nov; 15(11):84.Ehlers MR, Rigby MR
  • Type 1 diabetes (T1D) is a chronic autoimmune disease that leads to progressive destruction of pancreatic beta cells. Compared to healthy controls, a characteristic feature of patients with T1D is the presence of self-reactive T cells with a memory phenotype. These autoreactive memory T cells in both the CD4(+) and CD8(+) compartments are likely to be long-lived, strongly responsive to antigenic …
  • Unusual case of B cell lymphoma after immunosuppressive treatment for psoriasis. [Case Reports]
    World J Hepatol. 2015 Apr 18; 7(5):814-8.Nosotti L, Baiocchini A, … Del Nonno F
  • Lymphomas may be induced by the systemic immunosuppressive therapies used to treat psoriasis, such as ciclosporin, methotrexate and tumour necrosis factor (TNF)-α blockers. The biologic agents currently used in psoriasis include alefacept, efalizumab, and the TNF-α antagonists etanercept, infliximab, and adalimumab. Infections and cancer are the main possible consequences of intended or unexpecte…
New Search Next